Virpax Pharmaceuticals Receives Nasdaq Panel Decision, Granted Listing Continuation with Conditions
On January 6, 2025, Virpax Pharmaceuticals, Inc. announced in a Form 8-K filing that it had received a decision from the Nasdaq Hearings Panel regarding its listing on The Nasdaq Stock Market. The Panel granted the Company’s request to continue its listing, subject to specific conditions outlined in the decision. The Nasdaq Hearings Panel’s decision […]
More Stories
Trump Announces EPA Will Roll Back Biden-Era Methane Regulations on Oil and Gas Producers
By Tom Gantert President Donald Trump announced Tuesday night in Lubbock, Texas, that his administration would roll back Biden-era methane...
Treasury Department Ends Ownership Reporting for US Small Businesses
By Owen Evans The Treasury Department on Aug. 11 finalized a rule permanently exempting U.S. companies and individuals from reporting...
US Consumer Confidence Rebounds Sharply in October: Conference Board
By Andrew Moran U.S. consumer confidence rebounded sharply in October, logging its first increase in four months, according to The...
Microsoft Offers Voluntary Buyouts to 60,000 Employees
By Andrew Moran Microsoft is offering voluntary buyouts to about 60,000 employees, around one-quarter of its total workforce, the software...
SBS Executives Questioned on Why Outlet Refers to Hamas as ‘Militants’ Not ‘Terrorists’
By Crystal-Rose Jones Executives at Australia’s multicultural Special Broadcasting Service (SBS) were asked to explain why the outlet does not...
What a New Roof Really Costs in Texas: A 2026 Budget Guide
The roof is the most expensive part of a house that most owners never look at. One spring storm can...